<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="hna" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">hna</book-part-id>
      <title-group>
        <title>Hereditary Neuralgic Amyotrophy</title>
        <alt-title alt-title-type="alt-title">Synonyms: Hereditary Brachial Plexus Neuropathy, Neuritis with Brachial Predilection</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>van Alfen</surname>
            <given-names>Nens</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Neurology and Clinical Neurophysiology <break/>Radboud University Nijmegen Medical Center<break/>Nijmegen, Netherlands</aff>
          <email>n.vanalfen@neuro.umcn.nl</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hannibal</surname>
            <given-names>Mark C</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Division of Genetics<break/>Department of Pediatrics and Communicable Diseases <break/>University of Michigan Medical School<break/>Ann Arbor, Michigan</aff>
          <email>hannibal@umich.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chance</surname>
            <given-names>Phillip F</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Division of Genetics and Developmental Medicine <break/>Department of Pediatrics <break/>Children&#x02019;s Hospital and Regional Medical Center <break/>University of Washington <break/>Seattle, Washington</aff>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>van Engelen</surname>
            <given-names>Baziel GM</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Neurology and Clinical Neurophysiology <break/>Radboud University Nijmegen Medical Center<break/>Nijmegen, Netherlands</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>27</day>
          <month>2</month>
          <year>2008</year>
        </date>
        <date date-type="updated">
          <day>6</day>
          <month>12</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="hmerf" document-type="chapter">Hereditary Myopathy with Early Respiratory Failure</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="hnpp" document-type="chapter">Hereditary Neuropathy with Liability to Pressure Palsies</related-object>
      <abstract id="hna.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Hereditary neuralgic amyotrophy (HNA) is characterized by sudden onset of severe, non-abating pain in the shoulder girdle and/or the upper limb and amyotrophy (muscle wasting or atrophy) that typically develops within two weeks of the onset of severe pain. Other sites may also be involved in an attack; sensory symptoms, present in the majority of affected individuals, can include hypoesthesia (decreased sensation) and paresthesias. Onset is typically in the second or third decade (median age 28 years). Although attacks appear to become less frequent with age, residual deficits accumulate with subsequent attacks. In some families, non-neurologic findings (characteristic craniofacial features, bifid uvula or cleft palate, short stature, and/or partial syndactyly of the fingers or toes) are present.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis of HNA is based on clinical findings. <italic toggle="yes">SEPT9</italic> is the only gene in which mutation is known to cause HNA; however, genetic heterogeneity exists.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Pain management is the primary goal of therapy and varies between acute and chronic stages. Corticosteroids have been used in the acute phase to shorten the duration of pain and improve recovery. Consultation with a physiatrist is recommended for chronic pain and persisting paresis. Patients with phrenic nerve palsy need specialized respiratory consultation and can benefit from noninvasive nocturnal positive pressure ventilation. Cleft palate is managed by standard protocols.</p>
          <p><italic toggle="yes">Surveillance</italic>: Follow up every six to 12 months after the initial diagnosis to identify chronic pain resulting from altered biomechanics of the shoulder or arm.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Overexertion of a limb with persistent weakness, especially if the scapula is unstable.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Hereditary neuralgic amyotrophy is inherited in an autosomal dominant manner. Most individuals diagnosed with HNA have an affected parent; the proportion of cases caused by a <italic toggle="yes">de novo</italic> pathogenic variant is unknown. Each child of an individual with HNA has a 50% chance of inheriting the pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant in the family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="hna.Diagnosis">
        <title>Diagnosis</title>
        <sec id="hna.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Hereditary neuralgic amyotrophy (HNA) is an episodic disorder diagnosed clinically using criteria developed by the European CMT Consortium; see modified criteria (<xref ref-type="table" rid="hna.T.hna_diagnostic_criteria">Table 1</xref>) and <xref ref-type="bibr" rid="hna.REF.kuhlenb_umer.2000.515">Kuhlenb&#x000e4;umer et al [2000]</xref>.</p>
          <p>Sensory and motor nerves are typically affected; occasionally autonomic nerve injury also occurs.</p>
          <p>HNA is characterized in 95% of cases by the following:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Sudden onset of severe, non-abating pain</bold> in the shoulder girdle and/or the upper limb. The pain may be unusually debilitating and, in some cases, even refractory to narcotic medications. The intense pain typically lasts for up to several weeks and may give way to a chronic aching pain in the limb persisting for months [<xref ref-type="bibr" rid="hna.REF.van_alfen.2006.438">van Alfen &#x00026; van Engelen 2006</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Amyotrophy (muscle wasting or atrophy)</bold> that typically develops within two weeks of the onset of severe pain [<xref ref-type="bibr" rid="hna.REF.van_alfen.2006.438">van Alfen &#x00026; van Engelen 2006</xref>]</p>
            </list-item>
          </list>
          <table-wrap id="hna.T.hna_diagnostic_criteria" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>HNA Diagnostic Criteria</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Feature</th>
                  <th id="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Inclusion Criteria</th>
                  <th id="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Compatible Criteria</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Age of onset</bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Second or third decade of life (median: 28 years)</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Earlier or later onset</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Clinical manifestations</bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Acute, uni- or bilateral brachial plexopathy</p>
                      </list-item>
                      <list-item>
                        <p>Severe pain preceding the onset of weakness by days to a few weeks</p>
                      </list-item>
                      <list-item>
                        <p>Predominantly motor deficits</p>
                      </list-item>
                      <list-item>
                        <p>Number of episodes variable (1-20)</p>
                      </list-item>
                      <list-item>
                        <p>Precipitating factors: infections, immunizations, surgery, parturition, unusually strenuous exercise of the affected limb, exposure to cold</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Attack recurrence (75%)</p>
                      </list-item>
                      <list-item>
                        <p>Sensory symptoms (70%)</p>
                      </list-item>
                      <list-item>
                        <p>Lumbar plexus (33%) and/or phrenic nerve (14%) involved</p>
                      </list-item>
                      <list-item>
                        <p>Cranial nerve involved&#x000a0;<sup>1</sup></p>
                      </list-item>
                      <list-item>
                        <p>Dysmorphic features&#x000a0;<sup>2</sup></p>
                      </list-item>
                      <list-item>
                        <p>Abortive attacks (pain is not followed by weakness)</p>
                      </list-item>
                      <list-item>
                        <p>Weakness preceding the onset of pain by days to weeks</p>
                      </list-item>
                      <list-item>
                        <p>Long intervals between attacks (up to many years)</p>
                      </list-item>
                      <list-item>
                        <p>No pain during an attack (5%)</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Family history</bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Autosomal dominant inheritance</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Simplex case (i.e., single occurrence in a family)</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Clinical examination&#x000a0;<sup>3</sup></bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Patchy or multifocal distribution of abnormalities</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>More prominent motor loss than sensory loss</p>
                      </list-item>
                      <list-item>
                        <p>Sensory abnormalities (80%)</p>
                      </list-item>
                      <list-item>
                        <p>Autonomic symptoms (15%)&#x000a0;<sup>4</sup></p>
                      </list-item>
                      <list-item>
                        <p>Mononeuropathy&#x000a0;<sup>5</sup></p>
                      </list-item>
                      <list-item>
                        <p>Absent or diminished tendon reflexes in affected limbs</p>
                      </list-item>
                      <list-item>
                        <p>Muscle weakness and atrophy</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Course and severity&#x000a0;<sup>6</sup></bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Relapsing/remitting course with symptom-free intervals</p>
                      </list-item>
                      <list-item>
                        <p>Recovery incomplete; persisting neurologic deficit especially after repeated attacks in the same limb</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Complete recovery without residual deficit between attacks</p>
                      </list-item>
                      <list-item>
                        <p>Chronic undulating course without completely symptom-free intervals</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Electrophysiologic findings&#x000a0;<sup>7</sup></bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Signs of denervation or reinnervation in clinically weak muscles seen on electromyogram (EEG)</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Reduced amplitude of compound muscle action potential (CMAP) in muscles innervated by affected nerves</p>
                      </list-item>
                      <list-item>
                        <p>Reduced amplitudes of sensory nerve action potentials in affected nerves</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <bold>Molecular genetics&#x000a0;<sup>8</sup></bold>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Identification of a presumed pathogenic variant or duplication in <italic toggle="yes">SEPT9</italic></p>
                      </list-item>
                      <list-item>
                        <p>Linkage to the SEPT9 locus on chromosome 17q25</p>
                      </list-item>
                    </list>
                  </td>
                  <td headers="hd_h_hna.T.hna_diagnostic_criteria_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <list list-type="bullet">
                      <list-item>
                        <p>Absence of linkage to the SEPT9 locus on chromosome 17q25</p>
                      </list-item>
                    </list>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Modified from <xref ref-type="bibr" rid="hna.REF.kuhlenb_umer.2000.515">Kuhlenb&#x000e4;umer et al [2000]</xref></p>
              </fn>
              <fn id="hna.TF.1.1">
                <label>1. </label>
                <p>Most commonly recurrent laryngeal nerve (19%) or facial nerve</p>
              </fn>
              <fn id="hna.TF.1.2">
                <label>2. </label>
                <p>Most commonly ocular hypotelorism, epicanthal folds, cleft palate, bifid uvula, excessive neck or arm skin folds</p>
              </fn>
              <fn id="hna.TF.1.3">
                <label>3. </label>
                <p>Exclusion criterion: Signs of generalized neuropathy</p>
              </fn>
              <fn id="hna.TF.1.4">
                <label>4. </label>
                <p>Such as abnormal sweating in affected arm or, rarely, Horner syndrome</p>
              </fn>
              <fn id="hna.TF.1.5">
                <label>5. </label>
                <p>Most commonly long thoracic, anterior interosseus, or phrenic nerve</p>
              </fn>
              <fn id="hna.TF.1.6">
                <label>6. </label>
                <p>Exclusion criterion: Slow progression of motor impairment over &#x0003e;3 months</p>
              </fn>
              <fn id="hna.TF.1.7">
                <label>7. </label>
                <p>Exclusion criterion: Electrophysiologic signs of systemic generalized neuropathy</p>
              </fn>
              <fn id="hna.TF.1.8">
                <label>8. </label>
                <p>Exclusion criteria: a <italic toggle="yes">PMP22</italic> deletion or pathogenic variant (chromosome 17p11.2) that is diagnostic of <related-object link-type="booklink" source-id="gene" document-id="hnpp" document-type="chapter">hereditary neuropathy with liability to pressure palsies</related-object> (HNPP)</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="hna.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">SEPT9</italic> is the only gene in which mutation is known to cause HNA.</p>
          <p><bold>Evidence for locus heterogeneity.</bold> In at least five reported families, markers flanking the SEPT9 locus do not segregate with the HNA phenotype, suggesting the involvement of one or more as-yet unknown genes [<xref ref-type="bibr" rid="hna.REF.van_alfen.2000.718">van Alfen et al 2000</xref>, <xref ref-type="bibr" rid="hna.REF.kuhlenb_umer.2001.861">Kuhlenb&#x000e4;umer et al 2001</xref>, <xref ref-type="bibr" rid="hna.REF.watts.2001.675">Watts et al 2001</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p>The percentage of families in the US who appear not to be genetically linked to the SEPT9 locus is estimated at 15%.</p>
            </list-item>
            <list-item>
              <p>The percentage of families in other countries (e.g., the Netherlands) who appear not to be genetically linked to the SEPT9 locus may be much higher [unpublished/preliminary data].</p>
            </list-item>
          </list>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <table-wrap id="hna.T.summary_of_molecular_genetic_testi" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Hereditary Neuralgic Amyotrophy</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of HNA Attributed to Mutation of This Gene</th>
                  <th id="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Pathogenic Variants Detected&#x000a0;<sup>2</sup></th>
                  <th id="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">SEPT9</italic>
                  </td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_2" rowspan="2" valign="middle" align="left" colspan="1">~55%&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">See footnote 6</td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">(Multi)exon or whole-gene duplication&#x000a0;<sup>8</sup></td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">See footnote 9</td>
                </tr>
                <tr>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">~45%</td>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_hna.T.summary_of_molecular_genetic_testi_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="hna.TF.2.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="hna" object-id="hna.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="hna.TF.2.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="hna.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
              </fn>
              <fn id="hna.TF.2.3">
                <label>3. </label>
                <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
              </fn>
              <fn id="hna.TF.2.4">
                <label>4. </label>
                <p>The proportion may be higher or lower depending on country or region of origin [<xref ref-type="bibr" rid="hna.REF.van_alfen.2011.315">van Alfen 2011</xref>].</p>
              </fn>
              <fn id="hna.TF.2.5">
                <label>5. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="hna.TF.2.6">
                <label>6. </label>
                <p>In families with HNA linked to <italic toggle="yes">SEPT9</italic>, sequence analysis identified a sequence variant in 8/42 families [<xref ref-type="bibr" rid="hna.REF.hannibal.2009.1755">Hannibal et al 2009</xref>] a roughly 20% pathogenic variant detection rate.</p>
              </fn>
              <fn id="hna.TF.2.7">
                <label>7. </label>
                <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="hna.TF.2.8">
                <label>8. </label>
                <p>Both a founder duplication and nonrecurrent duplications (with unique breakpoints) have been reported [<xref ref-type="bibr" rid="hna.REF.landsverk.2009.1200">Landsverk et al 2009</xref>, <xref ref-type="bibr" rid="hna.REF.collie.2010.601">Collie et al 2010</xref>]. See <xref ref-type="sec" rid="hna.Molecular_Genetics">Molecular Genetics</xref>.</p>
              </fn>
              <fn id="hna.TF.2.9">
                <label>9. </label>
                <p>In families with HNA linked to <italic toggle="yes">SEPT9,</italic> CMA identified the founder haplotype duplication in 12/55 families [<xref ref-type="bibr" rid="hna.REF.landsverk.2009.1200">Landsverk et al 2009</xref>] and a tandem duplication in 6/55 families [<xref ref-type="bibr" rid="hna.REF.collie.2010.601">Collie et al 2010</xref>], a roughly 33% variant detection rate.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="hna.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Confirmation of the diagnosis in persons in whom a clinical diagnosis of HNA is suspected requires molecular genetic testing to identify the pathogenic allelic variant in <italic toggle="yes">SEPT9</italic>.</p>
            </list-item>
            <list-item>
              <p>If sequence analysis of <italic toggle="yes">SEPT9</italic> does not identify a pathogenic variant, deletion/duplication analysis should be considered.</p>
            </list-item>
          </list>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the pathogenic variant in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="hna.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="hna.Clinical_Description">
          <title>Clinical Description</title>
          <p><bold>Neuralgic amyotrophy attacks.</bold> Typically, onset of painful attacks in hereditary neuralgic amyotrophy (HNA) occurs in the second or third decade of life (median age of onset 28 years), but children as young as age one year have had attacks. The male to female ratio is 2:1.</p>
          <p>The attacks comprise severe aching, burning, or stabbing pains, most often in the shoulders, neck, and/or arm region, followed by multifocal atrophy and paresis. Usually the brachial plexus is involved. In one third of cases, the involvement is bilateral, although severity is usually asymmetric. Attacks appear to become less frequent with age.</p>
          <p>The most comprehensive review of attack features in both HNA and sporadic idiopathic neuralgic amyotrophy (see <xref ref-type="sec" rid="hna.Differential_Diagnosis">Differential Diagnosis</xref>) was reported by <xref ref-type="bibr" rid="hna.REF.van_alfen.2006.438">van Alfen &#x00026; van Engelen [2006]</xref>. The pain lasts an average of four weeks. Weakness most often begins in the periscapular or perihumeral muscles (see <xref ref-type="fig" rid="hna.F1">Figure 1</xref>) between one and two weeks after the onset of pain. In some instances the onset of weakness may follow within 24 hours of the onset of pain.</p>
          <p>The long thoracic and suprascapular nerves are affected in about 70% of cases. Other frequently involved nerves are the axillary, musculocutanous, radial, and anterior interosseus. Lower plexus involvement (median motor and ulnar distribution) occurs in about 5% [<xref ref-type="bibr" rid="hna.REF.van_alfen.2011.315">van Alfen 2011</xref>].</p>
          <p>In many cases the muscle weakness may go unnoticed, especially if it only affects the periscapular muscles such as the serratus anterior, rhomboids or subscapularis. Functionally, however, the resulting scapular instability often causes pain, limitation of movement, and exercise intolerance of the affected limb that can persist for months to years.</p>
          <p>Sensory symptoms, present in the majority of affected individuals, are often overlooked. They can include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Hypoesthesia (decreased sensation) located anywhere from the shoulder to the fingertips; found in 85% of individuals</p>
            </list-item>
            <list-item>
              <p>Paresthesias; reported in more than 50% of attacks</p>
            </list-item>
            <list-item>
              <p>Vasomotor changes in the arm; reported in 15% of attacks. This autonomic dysfunction of the cervical sympathetic nerves can result in hand edema or vasomotor instability [<xref ref-type="bibr" rid="hna.REF.van_alfen.2007.695">van Alfen 2007</xref>].</p>
            </list-item>
          </list>
          <p>While the shoulder and arm are primarily affected by attacks in HNA, other sites that may also be involved in an attack include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Lumbosacral plexus in ~33% of attacks</p>
            </list-item>
            <list-item>
              <p>Phrenic nerve palsy in 14% of attacks; may cause orthopnea, respiratory distress and sleep disturbance</p>
            </list-item>
            <list-item>
              <p>Recurrent laryngeal nerve in 3% of attacks; may cause vocal cord paresis resulting in hoarseness and hypophonia</p>
            </list-item>
            <list-item>
              <p>Facial nerve or other cranial nerves (rarely)</p>
            </list-item>
          </list>
          <p>Two patterns of HNA attacks are described:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Common.</bold> Classic remitting/relapsing type, characterized by rapid onset of attacks accompanied by complete or substantial slow recovery</p>
            </list-item>
            <list-item>
              <p><bold>Rare.</bold> Chronic undulating type, characterized by slower onset of persistent pain with a protracted fluctuating but unremitting course of attacks resulting in severe residual neurologic deficits [<xref ref-type="bibr" rid="hna.REF.van_alfen.2000.718">van Alfen et al 2000</xref>]</p>
            </list-item>
          </list>
          <p>The prognosis for eventual recovery of neurologic function in neuralgic amyotrophy is guarded, with residual deficits accumulating with additional attacks.</p>
          <p><bold>Characteristic physical features.</bold> In some families, HNA is associated with non-neurologic physical features that allow assessment of the risk for HNA before attacks appear. Typically, these non-neurologic findings include short stature; partial syndactyly of the fingers or toes; characteristic craniofacial features with relatively closely spaced eyes, short palpebral fissures, and epicanthus; and cleft (bifid) uvula or cleft palate [<xref ref-type="bibr" rid="hna.REF.jeannet.2001.1963">Jeannet et al 2001</xref>]. The ocular hypotelorism in some families is striking, with interpupillary distance typically between -1 and -2 standard deviations. As pointed out by several authors, the facial features of persons with HNA resemble portraits painted by the artist Amedeo Modigliani [<xref ref-type="bibr" rid="hna.REF.dunn.1978.28">Dunn et al 1978</xref>].</p>
          <p>Excessive partial circumferential skin folds of the neck and arms are also characteristic features [<xref ref-type="bibr" rid="hna.REF.jeannet.2001.1963">Jeannet et al 2001</xref>].</p>
          <p><bold>Pathophysiology.</bold> Attacks may be triggered by periods of physical, immunologic, or emotional stress. Females appear to have a predilection for attacks after childbirth. This, and association of attacks following immunizations and recent viral or bacterial infections, raise a possible role of an immune system trigger. Prior strenuous usage of the upper limbs has also been reported to precipitate attacks suggesting that local trauma or ischemia of the brachial plexus resulting from compression between muscle groups may underlay the plexopathy, making it more susceptible to (auto-) immune damage.</p>
          <p>Biopsy of sural or superficial radial nerves is rarely performed in this disorder. The only finding described in the majority of biopsies is focal decreases in myelinated fibers within individual nerve fascicles [<xref ref-type="bibr" rid="hna.REF.van_alfen.2005.445">van Alfen et al 2005</xref>]. In one report, multiple epineural perivascular mononuclear infiltrates without necrosis were seen in three of four upper-extremity nerve biopsies, obtained three weeks, three months, and seven months after onset of an attack [<xref ref-type="bibr" rid="hna.REF.klein.2002.45">Klein et al 2002</xref>]. These infiltrates were accompanied by active axonal degeneration.</p>
        </sec>
        <sec id="hna.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>In families with pathogenic variants in <italic toggle="yes">SEPT9</italic>, non-neurologic features may or may not be observed. In many cases these dysmorphisms are related to the <italic toggle="yes">SEPT9</italic> pathogenic variant p.Arg88Trp [<xref ref-type="bibr" rid="hna.REF.van_alfen.2011.315">van Alfen 2011</xref>]. Generally, non-neurologic features are rarely observed in Dutch individuals, which could indicate that the p.Arg88Trp pathogenic variant is rare in this population.</p>
          <p>In one family that appears to have HNA but does not segregate with markers flanking <italic toggle="yes">SEPT9</italic>, affected individuals show the chronic undulating phenotype: slowly increasing pain before the onset of the first severe attack followed by an undulating course without complete recovery or cessation of symptoms [<xref ref-type="bibr" rid="hna.REF.van_alfen.2000.718">van Alfen et al 2000</xref>]. Whether other families with the chronic undulating phenotype are also not genetically linked to <italic toggle="yes">SEPT9</italic> is unknown.</p>
        </sec>
        <sec id="hna.Penetrance">
          <title>Penetrance</title>
          <p>Studies based on clinical criteria suggest that the penetrance is between 80% and greater than 90% for all individuals with HNA, not taking into account the underlying cause of the disorder [<xref ref-type="bibr" rid="hna.REF.kuhlenb_umer.2000.515">Kuhlenb&#x000e4;umer et al 2000</xref>, <xref ref-type="bibr" rid="hna.REF.van_alfen.2007.695">van Alfen 2007</xref>].</p>
          <p>Data regarding penetrance in relation to <italic toggle="yes">SEPT9</italic> mutation status have not yet been published.</p>
        </sec>
        <sec id="hna.Nomenclature">
          <title>Nomenclature</title>
          <p>Out-of-date terms previously used for hereditary neuralgic amyotrophy include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Familial brachial plexus neuritis</p>
            </list-item>
            <list-item>
              <p>Heredofamilial neuritis with brachial plexus predilection</p>
            </list-item>
          </list>
        </sec>
        <sec id="hna.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of HNA is unknown. About 300 families are known worldwide.</p>
          <p>The prevalence of HNA is estimated to be about an order of magnitude less than that of idiopathic neuralgic amyotrophy (Parsonage-Turner syndrome), which has an estimated incidence of 1.64:100,000/year to 3:100,000/year [<xref ref-type="bibr" rid="hna.REF.beghi.1985.320">Beghi et al 1985</xref>, <xref ref-type="bibr" rid="hna.REF.macdonald.2000.665">MacDonald et al 2000</xref>].</p>
          <p>Prevalence of any brachial neuritis was estimated to be 3:10,000 in the London (UK) area [<xref ref-type="bibr" rid="hna.REF.macdonald.2000.665">MacDonald et al 2000</xref>].</p>
          <p>The actual prevalence of these disorders is likely to be higher because of underdiagnosis. Sixty percent of individuals with neuralgic amyotrophy seen at the Nijmegen clinical center were first diagnosed with a different disorder [<xref ref-type="bibr" rid="hna.REF.van_alfen.2006.438">van Alfen &#x00026; van Engelen 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="hna.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No other phenotypes are known to be associated with germline pathogenic variants in <italic toggle="yes">SEPT9</italic>.</p>
        <p>The <italic toggle="yes">MLL</italic> oncogene may fuse with <italic toggle="yes">SEPT9</italic> in somatic cells to give rise to some forms of myelodysplasia and acute myeloid leukemia (AML).</p>
        <p>Note: There is no known relationship between HNA and AML.</p>
      </sec>
      <sec id="hna.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Acute pain in the shoulder and upper arm region may be caused by neurologic or non-neurologic disorders.</p>
        <list list-type="bullet">
          <list-item>
            <p>If all the pain, paresis, and sensory symptoms are in the same cervical root distribution, a degenerative or acute disk rupture cervical radiculopathy must be considered.</p>
          </list-item>
          <list-item>
            <p>Cervical spondylosis may have referred arm pain that is position- or activity-dependent, with no focal deficits and a fluctuating course. Imaging studies such as MRI or CT scan may exclude vertebral or space-occupying causes. The focus, however, should be on the clinical picture, as approximately 50% of affected adults usually show degenerative changes on cervical spine MRI.</p>
          </list-item>
          <list-item>
            <p>Complex regional pain syndrome involving the shoulder or arm has predominantly vasomotor symptoms, with subacute onset of diffuse pain and weakness with progression.</p>
          </list-item>
          <list-item>
            <p>Other rare neurologic disorders could include mononeuritis multiplex (peripheral nervous system vasculitis), multifocal motor neuropathy, or brachial amyotrophic diplegia, but these tend to have subacute onset and the latter two disorders are usually painless. Electromyography (EMG) and nerve conduction studies help to distinguish radiculopathies; examination of unaffected limbs excludes generalized peripheral neuropathies.</p>
          </list-item>
          <list-item>
            <p>In extremely rare cases, an acute painful brachial plexopathy is found as the only sign of an underlying <related-object link-type="booklink" source-id="gene" document-id="hnpp" document-type="chapter">hereditary neuropathy with liability to pressure palsies</related-object> (HNPP). HNPP is an autosomal dominant disorder caused by the deletion or mutation of <italic toggle="yes">PMP22</italic>. Usually there is a family history of nerve damage resulting from minor stretch or compressive trauma.</p>
          </list-item>
          <list-item>
            <p>Shoulder joint pathology (e.g., bursitis, calcifying tendonitis) or rotator cuff injury may cause pain that is exacerbated by joint movement and relieved by rest or passive immobilization.</p>
          </list-item>
        </list>
        <p>Brachial plexopathy may also be caused by trauma, surgery, or prior irradiation:</p>
        <list list-type="bullet">
          <list-item>
            <p>Lower plexus lesions may be seen in the case of a Pancoast tumor or true neurogenic thoracic outlet syndrome.</p>
          </list-item>
          <list-item>
            <p>A peripheral nerve or nerve sheath tumor may involve the plexus, as could direct peripheral nervous system infections such as neuroborreliosis or HIV.</p>
          </list-item>
        </list>
        <p>The main differential diagnosis in an individual presenting with an acute-onset, painful, multifocal, brachial plexopathy is neuralgic amyotrophy in either its hereditary or idiopathic form. HNA is clinically similar to its sporadic counterpart, idiopathic neuralgic amyotrophy (INA). The disorders share the same precipitating factors, signs, and symptoms. INA, also called brachial neuritis or Parsonage-Turner syndrome, is estimated to be about ten times more common than HNA. HNA is distinguished from INA by its familial recurrence, earlier average age of onset, more severe pain in the acute stage, more frequent involvement of nerves outside of the brachial plexus, higher rate of recurrence, and greater eventual disability. However, no single feature in a given individual can distinguish hereditary from sporadic neuralgic amyotrophy; this distinction is based on a positive family history and/or the presence of the typical dysmorphic features.</p>
        <p>Excluding the <related-object link-type="booklink" source-id="gene" document-id="hpe-overview" document-type="chapter">holoprosencephaly syndromes</related-object>, a couple of syndromes known to share some of the craniofacial features of HNA are autosomal dominant Schilbach-Rott syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/164220">164220</ext-link>) and Michelin tire baby syndrome (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/156610">156610</ext-link>).</p>
        <list list-type="bullet">
          <list-item>
            <p>Like HNA, Schilbach-Rott syndrome is characterized by short stature, cutaneous syndactyly, ocular hypotelorism, and cleft palate [<xref ref-type="bibr" rid="hna.REF.joss.2002.105">Joss et al 2002</xref>]. The families reported do not have neuralgic amyotrophy.</p>
          </list-item>
          <list-item>
            <p>A subset of individuals with Michelin tire baby syndrome (with what now may be known as &#x0201c;circumferential skin creases, Kunze type&#x0201d;) also may share the following with HNA: craniofacial features (including relatively closely spaced eyes and short palpebral fissures), cleft palate, and circumferential skin folds [<xref ref-type="bibr" rid="hna.REF.wouters.2011.236">Wouters et al 2011</xref>].</p>
          </list-item>
        </list>
      </sec>
      <sec id="hna.Management">
        <title>Management</title>
        <sec id="hna.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with hereditary neuralgic amyotrophy, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Comprehensive neuromuscular evaluation</p>
            </list-item>
            <list-item>
              <p>Needle EMG to identify the severity and extent of denervation and reinnervation</p>
            </list-item>
            <list-item>
              <p>Evaluation of phrenic nerve involvement by chest x-ray, ultrasound/fluoroscopic evaluation of diaphragm movement, and pulmonary function tests in seated and supine positions</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
          <p>For a practical overview of the physical examination and the value of additional investigations in neuralgic amyotrophy see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pn.bmj.com/content/6/5/298.full">pn.bmj.com</ext-link>.</p>
        </sec>
        <sec id="hna.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Currently, no effective therapy is proven to abort or shorten an HNA attack.</p>
          <p>Treatment of acute episodes of pain and weakness with corticosteroids has been proposed based on retrospective analysis of cases [<xref ref-type="bibr" rid="hna.REF.van_alfen.2009.cd006976">van Alfen et al 2009</xref>, <xref ref-type="bibr" rid="hna.REF.van_eijk.2009.1120">van Eijk et al 2009</xref>]. These reports summarize retrospective, anecdotal evidence that corticosteroids can have a favorable effect on pain and recovery. Additional immunomodulatory treatments with such agents as corticosteroids and immune globulin may be considered, but no prospective trials have been performed [<xref ref-type="bibr" rid="hna.REF.van_alfen.2009.cd006976">van Alfen et al 2009</xref>, <xref ref-type="bibr" rid="hna.REF.johnson.2011.304">Johnson et al 2011</xref>].</p>
          <p><bold>Pain management</bold> is the primary goal of therapy:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>In the acute stage,</bold> a combination of a long-acting nonsteroidal anti-inflammatory drug (NSAID) such as ketorolac and a narcotic such as controlled-release morphine are used.</p>
            </list-item>
            <list-item>
              <p><bold>In the second phase</bold> of chronic pain resulting from damaged, hypersensitive nerves, co-analgesics such as gabapentin, carbamazepine, and amitryptiline may be used.</p>
            </list-item>
            <list-item>
              <p><bold>In the third chronic phase,</bold> persistent pain in the neck and shoulder region usually points to strain of the paretic or compensating muscles or to a complication in the glenohumeral joint, such as rotator cuff pathology. As the weakness has to recover by itself, therapy focuses on arm support in a sling, rest, physical therapy, range of motion stretching, and modification of activities. This rehabilitation and prevention of further injury is best managed by a physiatrist.</p>
            </list-item>
          </list>
          <p><bold>For persistent paresis,</bold> physical therapy is recommended to maintain exercise tolerance and prevent joint or ligament contractures. Care must be taken to avoid post-exercise pain in the affected area, as this is often a sign of strain. In this case, exercise should be temporarily deferred, or at least be without extra added weights and with fewer repetitions per set. The patient must find his or her personal level of exercise tolerance; in practice, this is often much lower than estimated (or desired) by the patient or therapist.</p>
          <p>For severe paresis of the serratus anterior muscle persisting more than one year, corrective surgery can be considered to increase scapular stability, for example by a split pectoralis major muscle transfer.</p>
          <p>Patients with phrenic nerve palsy need consultation with a respiratory specialist and can benefit from noninvasive nocturnal positive pressure ventilation.</p>
          <p>For a clinical overview of neurologic and rehabilitative management, see <xref ref-type="bibr" rid="hna.REF.van_alfen.2007.695">van Alfen [2007]</xref>.</p>
          <p><bold>Cleft palate</bold> is best managed by a local craniofacial team.</p>
        </sec>
        <sec id="hna.Surveillance">
          <title>Surveillance</title>
          <p>As chronic pain resulting from altered biomechanics of the shoulder or upper extremity tends to develop during the first one to two years, follow up every six to 12 months after the initial diagnosis is recommended.</p>
        </sec>
        <sec id="hna.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Although immunizations have been known to precede and possibly trigger attacks, it is still recommended that they be given on the usual recommended schedule because the risk of immunization precipitating an attack is probably low [based on expert opinion].</p>
          <p>Patients with persistent weakness and especially scapular instability should be cautioned to avoid overexerting the affected limb.</p>
        </sec>
        <sec id="hna.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="hna.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="hna.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Women with HNA should be monitored in the post-partum interval for the development of symptoms. Prompt treatment with corticosteroids or similar agents may ameliorate an HNA attack.</p>
        </sec>
        <sec id="hna.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>In an open-label study of oral prednisone in adults with INA or HNA (60 mg/day for one week, followed by a one week taper by 10 mg/day with a last dose of 5 mg) the only statistically significant finding was a reduction in the time for paresis recovery [<xref ref-type="bibr" rid="hna.REF.van_alfen.2006.438">van Alfen &#x00026; van Engelen 2006</xref>]. Other variables showed no statistical difference from an untreated group of persons with neuralgic amyotrophy; variables included the duration of the initial pain, maximum present Numerical Rating Scale score and use of analgesics, the occurrence of a chronic pain syndrome, maximum Medical Research Council level of strength recovery, complications such as frozen shoulder or shoulder dislocation, and Rankin score.</p>
          <p>An additional review of the Dutch experience revealed the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Relative to the untreated patients, a significantly higher proportion of the patients receiving oral prednisolone recovered early from their pareses.</p>
            </list-item>
            <list-item>
              <p>Taken in the first month, prednisolone tended to decrease the average duration of the initial pain, although this finding was not statistically significant.</p>
            </list-item>
            <list-item>
              <p>Functional recovery set in earlier, with significantly more treated patients achieving full recovery within a year or reporting a &#x02018;&#x02018;good&#x02019;&#x02019; outcome within six months.</p>
            </list-item>
            <list-item>
              <p>Side effects occurred in 20% of patients, but did not result in discontinuation of treatment [<xref ref-type="bibr" rid="hna.REF.van_eijk.2009.1120">van Eijk et al 2009</xref>].</p>
            </list-item>
          </list>
          <p>A randomized placebo-controlled trial of oral prednisone conducted in the Netherlands was terminated after three years because of insufficient recruitment within the specified time frame. No treatment effect could be demonstrated in the 13 persons in the primary treatment and placebo arm; however, the small number of participants precluded any definite conclusions.</p>
          <p>Experimental immunosuppressive therapies that have been used in other inflammatory polyneuropathies, but for which there are limited data available for treatment of attacks in HNA, include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Methylprednisolone, intravenous 30 mg/kg (or 1.0 g in adults) every 24 hours for three days [<xref ref-type="bibr" rid="hna.REF.klein.2002.45">Klein et al 2002</xref>, <xref ref-type="bibr" rid="hna.REF.nakajima.2006.227">Nakajima et al 2006</xref>]. Cessation or tapering of corticosteroid therapy has resulted in relapse.</p>
            </list-item>
            <list-item>
              <p>Intravenous immune globulin, 0.4 g/kg/day for five days [<xref ref-type="bibr" rid="hna.REF.ardolino.2003.550">Ardolino et al 2003</xref>, <xref ref-type="bibr" rid="hna.REF.moriguchi.2011.107">Moriguchi et al 2011</xref>]</p>
            </list-item>
          </list>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="hna.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="hna.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Hereditary neuralgic amyotrophy is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="hna.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with hereditary neuralgic amyotrophy have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with hereditary neuralgic amyotrophy may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include a clinical evaluation for findings of HNA. Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
          </list>
          <p>Note: (1) Although most individuals diagnosed with hereditary neuralgic amyotrophy have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. (2) If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the variant and may be mildly/minimally affected.</p>
          <p><bold>Sibs of a proband.</bold> The risk to the sibs of the proband depends on the genetic status of the proband's parents:</p>
          <list list-type="bullet">
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with hereditary neuralgic amyotrophy has a 50% chance of inheriting the pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected, his or her family members may be at risk.</p>
        </sec>
        <sec id="hna.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, it is likely that the proband has the disorder as a result of a <italic toggle="yes">de novo</italic> pathogenic variant in either <italic toggle="yes">SEPT9</italic> or another as-yet unknown gene. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>Testing of at-risk asymptomatic adults.</bold> Although uncommonly requested, testing of at-risk asymptomatic adults for hereditary neuralgic amyotrophy is possible using the techniques described in <xref ref-type="sec" rid="hna.Molecular_Genetic_Testing">Molecular Genetic Testing</xref>. Such testing is not useful in predicting whether symptoms will occur, or if they do, what the age of onset, severity and type of symptoms, or rate of disease progression in asymptomatic individuals will be. When testing at-risk individuals for hereditary neuralgic amyotrophy, an affected family member must be tested first to confirm the molecular diagnosis in the family.</p>
          <p>Testing for the pathogenic allelic variant in the absence of definite symptoms of the disease is predictive testing. At-risk asymptomatic adult family members may seek testing in order to make personal decisions regarding reproduction, financial matters, and career planning. Others may have different motivations including simply the "need to know." Testing of asymptomatic at-risk adult family members usually involves pre-test interviews in which the motives for requesting the test, the individual's knowledge of hereditary neuralgic amyotrophy, the possible impact of positive and negative test results, and neurologic status are assessed. Those seeking testing should be counseled regarding possible problems that they may encounter with regard to health, life, and disability insurance coverage, employment and educational discrimination, and changes in social and family interaction. Other issues to consider are implications for the at-risk status of other family members. Informed consent should be procured and records kept confidential. Individuals with a positive test result need arrangements for long-term follow up and evaluations.</p>
          <p><bold>Molecular genetic testing of asymptomatic individuals younger than age 18 years.</bold> Because no proven preventive or ameliorating treatment is available, individuals younger than age 18 years who are at risk of having inherited and developing HNA are typically not offered testing during childhood. The principal arguments against testing asymptomatic individuals during childhood are that it removes their choice to know or not know this information, it raises the possibility of stigmatization within the family and in other social settings, and it could have serious educational and career implications.</p>
          <p>Individuals younger than age 18 years who are symptomatic usually benefit from having a specific diagnosis established.</p>
          <p>See also the National Society of Genetic Counselors <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nsgc.org/p/bl/et/blogaid=860">position statement</ext-link> on genetic testing of minors for adult-onset conditions and the American Academy of Pediatrics and American College of Medical Genetics and Genomics <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">policy statement</ext-link>: ethical and policy issues in genetic testing and screening of children.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="hna.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">SEPT9</italic> pathogenic variant has been identified in an affected family member, prenatal testing or preimplantation genetic diagnosis for a pregnancy at increased risk for hereditary neuralgic amyotrophy may be an option that a couple may wish to consider.</p>
          <p>Requests for prenatal testing for conditions which (like hereditary neuralgic amyotrophy) do not affect intellect or life span are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="hna.Resources">
        <title>Resources</title>
      </sec>
      <sec id="hna.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">SEPT9</italic> and septin-9 protein have numerous published aliases, including MSF, SepD1, Ov/Br septin, and PNUTL4. At least 17 exons spanning 213 kilobases are used to generate alternatively spliced transcripts (see <related-object source-id="gene" document-id="hna" object-id="hna.molgen.TA">Table A</related-object>, <bold>Gene</bold>). In the seven most abundant transcripts, variation in splicing occurs in the alternate use of 5' exons to include 10-12 exons that generate polypeptides ranging from 586 to 335 amino acids. The three transcripts that encode the longest proteins encode short, distinct N-terminal polypeptides of 25 amino acids (septin-9 isoform a, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001113491.1">NM_001113491.1</ext-link>), 18 amino acids (septin-9 isoform b, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001113493.1">NM_001113493.1</ext-link>), and seven amino acids (septin-9 isoform c, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_006640.4">NM_006640.4</ext-link>).</p>
        <p><bold>Pathogenic variants.</bold> Three small intragenic pathogenic variants have been reported: a non-coding 5'-untranslated region variant and two missense variants, p.Arg88Trp and p.Ser93Phe [<xref ref-type="bibr" rid="hna.REF.kuhlenb_umer.2005.1044">Kuhlenb&#x000e4;umer et al 2005</xref>, <xref ref-type="bibr" rid="hna.REF.hannibal.2009.1755">Hannibal et al 2009</xref>]. Both missense variants occur within a 645-bp exon of <italic toggle="yes">SEPT9</italic> (hg18 chr17:72,909,736-72,910,380; p.Arg88Trp is a recurrent missense variant located at a presumably hypermutable CG dinucleotide [<xref ref-type="bibr" rid="hna.REF.kuhlenb_umer.2005.1044">Kuhlenb&#x000e4;umer et al 2005</xref>, <xref ref-type="bibr" rid="hna.REF.hannibal.2009.1755">Hannibal et al 2009</xref>, <xref ref-type="bibr" rid="hna.REF.klein.2009.238">Klein et al 2009</xref>, <xref ref-type="bibr" rid="hna.REF.ueda.2010.94">Ueda et al 2010</xref>]. See <xref ref-type="table" rid="hna.T.selected_sept9_pathogenic_variants">Table 3</xref>.</p>
        <p>Six intragenic duplications and one whole-gene duplication have been identified in families with HNA [<xref ref-type="bibr" rid="hna.REF.landsverk.2009.1200">Landsverk et al 2009</xref>, <xref ref-type="bibr" rid="hna.REF.collie.2010.601">Collie et al 2010</xref>]. Each of these minimally duplicates a 7,592-bp genomic region containing a 645-bp exon within <italic toggle="yes">SEPT9</italic> (hg18 coordinates chr17:72,904,532-72,912,123). A larger SEPT9 protein is produced from some of the intragenic duplication alleles.</p>
        <p>Note: Human Mar. 2006 (NCBI36/hg18) Browser Sequences are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genome.ucsc.edu/cgi-bin/hgTracks?hgsid=246236279&#x00026;chromInfoPage=">genome.ucsc.edu</ext-link>.</p>
        <table-wrap id="hna.T.selected_sept9_pathogenic_variants" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Selected <italic toggle="yes">SEPT9</italic> Pathogenic Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.-134G&#x0003e;C<break/>(SEPT9_v3 5'-UTR-131G&#x0003e;C)</td>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">--</td>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_006640.4">NM_006640.4</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_006631.2">NP_006631.2</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.262C&#x0003e;T</td>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg88Trp<break/>(SEPT9_v3 R88W)</td>
              </tr>
              <tr>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.278C&#x0003e;T</td>
                <td headers="hd_h_hna.T.selected_sept9_pathogenic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ser93Phe<break/>(SEPT9_v3 S93F)</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="hna.TF.3.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p>For more information, see <related-object source-id="gene" document-id="hna" object-id="hna.molgen.TA">Table A</related-object>.</p>
        <p><bold>Normal gene product.</bold>
<italic toggle="yes">SEPT9</italic> appears to be ubiquitously expressed, but studies of the distribution of septin-9 protein isoforms in normal tissues are limited. Septin-9 is thought to play a role in cytokinesis and tumorigenesis. The long isoforms of septin-9 have unique N-terminal polypeptides with a proline-rich domain. Only the septin proteins encoded by <italic toggle="yes">SEPT4</italic> also have a nonhomologous proline-rich domain. Septin-9 shares a polybasic and GTP-binding domain with all septins, but lacks a C-terminal coiled-coil domain found in all septins, except those encoded by <italic toggle="yes">SEPT9</italic>, <italic toggle="yes">SEPT3</italic>, and <italic toggle="yes">SEPT12</italic>. Septin-9 has been shown to be localized with other septins to intermediate filaments that associate with actin microfilaments and microtubules.</p>
        <p><bold>Abnormal gene product.</bold> Several hypotheses have arisen regarding the functional consequences of a <italic toggle="yes">SEPT9</italic> pathogenic variant. One report suggests that mutation of <italic toggle="yes">SEPT9</italic> results in alteration of a putative internal ribosome entry site in the mRNA transcript that controls the choice of the initiating ATG codon for protein translation [<xref ref-type="bibr" rid="hna.REF.mcdade.2007.742">McDade et al 2007</xref>]. Another paper proposes that the <italic toggle="yes">SEPT9</italic> pathogenic variants alter the interaction of septin-9 with septin-4 and perturb the regulation of septin-9-containing filaments by Rho/Rhotekin signaling [<xref ref-type="bibr" rid="hna.REF.sudo.2007.1005">Sudo et al 2007</xref>]. The limited range of pathogenic variants seen to date (i.e., 2 pathogenic missense variants with the 645-bp exon and <italic toggle="yes">SEPT9</italic> duplications that produce a larger protein product containing 2 tandem copies of the peptide encoded by the 645-bp exon) suggest that a novel gain-of-function mechanism may account for SEPT9 pathogenesis.</p>
      </sec>
      <sec id="hna.References">
        <title>References</title>
        <sec id="hna.Published_GuidelinesConsensus_Statem">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="hna.Published_GuidelinesConsensus_Statem.reflist0">
            <ref id="hna.REF1">
              <mixed-citation publication-type="web">Committee on Bioethics, Committee on Genetics, and American College of Medical Genetics and Genomics Social, Ethical, Legal Issues Committee. Ethical and policy issues in genetic testing and screening of children. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pediatrics.aappublications.org/content/131/3/620.full.pdf">online</ext-link>. 2013. Accessed 4-17-17.</mixed-citation>
            </ref>
            <ref id="hna.REF2">
              <mixed-citation publication-type="web">National Society of Genetic Counselors. Position statement on genetic testing of minors for adult-onset conditions. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nsgc.org/p/bl/et/blogaid=860">online</ext-link>. 2017. Accessed 4-17-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hna.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="hna.Literature_Cited.reflist0">
            <ref id="hna.REF.ardolino.2003.550">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ardolino</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbieri</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priori</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>High dose intravenous immune globulin in the treatment of hereditary recurrent brachial plexus neuropathy.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <volume>74</volume>
                <fpage>550</fpage>
                <pub-id pub-id-type="pmid">12640095</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.beghi.1985.320">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Beghi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurland</surname>
                    <given-names>LT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulder</surname>
                    <given-names>DW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicolosi</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1985</year>
                <article-title>Brachial plexus neuropathy in the population of Rochester, Minnesota, 1970-1981.</article-title>
                <source>Ann Neurol</source>
                <volume>18</volume>
                <fpage>320</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">2996415</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.collie.2010.601">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collie</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landsverk</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzzo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mefford</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buysse</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adkins</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knutzen</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnett</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>RH</given-names>
                    <suffix>Jr</suffix>
                  </name>
                  <name name-style="western">
                    <surname>Parry</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yum</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simpson</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olney</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannibal</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Non-recurrent SEPT9 duplications cause hereditary neuralgic amyotrophy.</article-title>
                <source>J Med Genet.</source>
                <year>2010</year>
                <volume>47</volume>
                <fpage>601</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">19939853</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.dunn.1978.28">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dunn</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Daube</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gomez</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <year>1978</year>
                <article-title>Heredofamilial branchial plexus neuropathy (hereditary neuralgic amyotrophy with branchial predilection) in childhood.</article-title>
                <source>Dev Med Child Neurol</source>
                <volume>20</volume>
                <fpage>28</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">205473</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.hannibal.2009.1755">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hannibal</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzzo</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchan</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knutzen</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnett</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landsverk</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>LeGuern</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bedford</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Worrall</surname>
                    <given-names>BB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lovitt</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Appel</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andermann</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>SEPT9 gene sequencing analysis reveals recurrent mutations in hereditary neuralgic amyotrophy.</article-title>
                <source>Neurology.</source>
                <volume>72</volume>
                <fpage>1755</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19451530</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.jeannet.2001.1963">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jeannet</surname>
                    <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Craniofacial and cutaneous findings expand the phenotype of hereditary neuralgic amyotrophy.</article-title>
                <source>Neurology</source>
                <volume>57</volume>
                <fpage>1963</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11739810</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.johnson.2011.304">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petraglia</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Logigian</surname>
                    <given-names>EL</given-names>
                  </name>
                </person-group>
                <article-title>Rapid resolution of severe neuralgic amyotrophy after treatment with corticosteroids and intravenous immunoglobulin.</article-title>
                <source>Muscle Nerve.</source>
                <year>2011</year>
                <volume>44</volume>
                <fpage>304</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">21717467</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.joss.2002.105">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Joss</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paterson</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donaldson</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolmie</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Cleft palate, hypotelorism, and hypospadias: Schilbach-Rott syndrome.</article-title>
                <source>Am J Med Genet</source>
                <volume>113</volume>
                <fpage>105</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">12400075</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.klein.2002.45">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyck</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedenberg</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burns</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windebank</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyck</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Inflammation and neuropathic attacks in hereditary brachial plexus neuropathy.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>73</volume>
                <fpage>45</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">12082044</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.klein.2009.238">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windebank</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyck</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedenberg</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dyck</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>SEPT9 mutations and a conserved 17q25 sequence in sporadic and hereditary brachial plexus neuropathy.</article-title>
                <source>Arch Neurol</source>
                <volume>66</volume>
                <fpage>238</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">19204161</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.kuhlenb_umer.2005.1044">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhlenb&#x000e4;umer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannibal</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schirmacher</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verpoorten</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meuleman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vriendt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>St&#x000f6;gbauer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Halfter</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Irobi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goossens</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del-Favero</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Betz</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hor</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurlemann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Airaksinen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mononen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serradell</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prats</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ringelstein</surname>
                    <given-names>EB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in SEPT9 cause hereditary neuralgic amyotrophy.</article-title>
                <source>Nat Genet.</source>
                <year>2005</year>
                <volume>37</volume>
                <fpage>1044</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16186812</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.kuhlenb_umer.2001.861">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhlenb&#x000e4;umer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meuleman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falck</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hunermund</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stogbauer</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Hereditary Neuralgic Amyotrophy (HNA) is genetically heterogeneous.</article-title>
                <source>J Neurol</source>
                <volume>248</volume>
                <fpage>861</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11697522</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.kuhlenb_umer.2000.515">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhlenb&#x000e4;umer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stogbauer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Diagnostic guidelines for hereditary neuralgic amyotrophy or heredofamilial neuritis with brachial plexus predilection. On behalf of the European CMT Consortium.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>10</volume>
                <fpage>515</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10996784</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.landsverk.2009.1200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Landsverk</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruzzo</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mefford</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buysse</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buchan</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eichler</surname>
                    <given-names>EE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petty</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knutzen</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barnett</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farlow</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Caress</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parry</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gardner</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hong</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simmons</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hannibal</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Duplication within the SEPT9 gene associated with a founder effect in North American families with hereditary neuralgic amyotrophy.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2009</year>
                <volume>18</volume>
                <fpage>1200</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19139049</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.macdonald.2000.665">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cockerell</surname>
                    <given-names>OC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sander</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shorvon</surname>
                    <given-names>SD</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK.</article-title>
                <source>Brain.</source>
                <volume>123</volume>
                <fpage>665</fpage>
                <lpage>76</lpage>
                <pub-id pub-id-type="pmid">10733998</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.mcdade.2007.742">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McDade</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hall</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russell</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Translational control of SEPT9 isoforms is perturbed in disease.</article-title>
                <source>Hum Mol Genet</source>
                <volume>16</volume>
                <fpage>742</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">17468182</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.moriguchi.2011.107">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moriguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takada</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kusunoki</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Four cases of anti-ganglioside antibody-positive neuralgic amyotrophy with good response to intravenous immunoglobulin infusion therapy.</article-title>
                <source>J Neuroimmunol</source>
                <volume>238</volume>
                <fpage>107</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">21872943</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.nakajima.2006.227">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nakajima</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujioka</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwamoto</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Partial but rapid recovery from paralysis after immunomodulation during early stage of neuralgic amyotrophy.</article-title>
                <source>Eur Neurol.</source>
                <volume>55</volume>
                <fpage>227</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16778440</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.sudo.2007.1005">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sudo</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iwamoto</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morishita</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nagata</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>SEPT9 sequence alternations causing hereditary neuralgic amyotrophy are associated with altered interactions with SEPT4/SEPT11 and resistance to Rho/Rhotekin-signaling.</article-title>
                <source>Hum Mutat</source>
                <volume>28</volume>
                <fpage>1005</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">17546647</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.ueda.2010.94">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ueda</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawamura</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tateishi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakae</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Motomura</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohyagi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kira</surname>
                    <given-names>JI</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Phenotypic spectrum of hereditary neuralgic amyotrophy caused by the SEPT9 R88W mutation.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <volume>81</volume>
                <fpage>94</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20019224</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_alfen.2007.695">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The neuralgic amyotrophy consultation.</article-title>
                <source>J Neurol</source>
                <volume>254</volume>
                <fpage>695</fpage>
                <lpage>704</lpage>
                <pub-id pub-id-type="pmid">17446996</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_alfen.2011.315">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Clinical and pathophysiological concepts of neuralgic amyotrophy.</article-title>
                <source>Nat Rev Neurol.</source>
                <volume>7</volume>
                <fpage>315</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">21556032</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_alfen.2005.445">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabreels-Festen</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ter Laak</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arts</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabreels</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Histology of hereditary neuralgic amyotrophy.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>76</volume>
                <fpage>445</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15716548</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_alfen.2006.438">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The clinical spectrum of neuralgic amyotrophy in 246 cases.</article-title>
                <source>Brain</source>
                <volume>129</volume>
                <fpage>438</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">16371410</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_alfen.2009.cd006976">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hughes</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis).</article-title>
                <source>Cochrane Database Syst Rev.</source>
                <issue>3</issue>
                <fpage>CD006976</fpage>
                <pub-id pub-id-type="pmid">19588414</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_alfen.2000.718">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinders</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabreels</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>The natural history of hereditary neuralgic amyotrophy in the Dutch population: two distinct types?</article-title>
                <source>Brain</source>
                <volume>123</volume>
                <fpage>718</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">10734003</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.van_eijk.2009.1120">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Eijk</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berrevoets</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Wilt</surname>
                    <given-names>GJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pillen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Evaluation of prednisolone treatment in the acute phase of neuralgic amyotrophy: an observational study.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>80</volume>
                <fpage>1120</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">19321467</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.watts.2001.675">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Watts</surname>
                    <given-names>GD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Briant</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Borreson</surname>
                    <given-names>TE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Windebank</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chance</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Evidence for genetic heterogeneity in hereditary neuralgic amyotrophy.</article-title>
                <source>Neurology</source>
                <volume>56</volume>
                <fpage>675</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11245726</pub-id>
              </element-citation>
            </ref>
            <ref id="hna.REF.wouters.2011.236">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wouters</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez Rodriguez</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dapena</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poorten</surname>
                    <given-names>VV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devriendt</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Esch</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Circumferential skin creases, cleft palate, typical face, intellectual disability and growth delay: "circumferential skin creases Kunze type</article-title>
                <source>Eur J Med Genet.</source>
                <volume>54</volume>
                <fpage>236</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21262397</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="hna.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="hna.Suggested_Reading.reflist0">
            <ref id="hna.REF.van_alfen.2000.328">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Alfen</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuuring</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Engelen</surname>
                    <given-names>BG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rotteveel</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabreels</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Idiopathic neuralgic amyotrophy in children. A distinct phenotype compared to the adult form.</article-title>
                <source>Neuropediatrics</source>
                <volume>31</volume>
                <fpage>328</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">11508556</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="hna.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="hna.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>6 December 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>27 February 2008 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>11 June 2007 (mch) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="hna.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Different presentations of upper-extremity atrophy and paresisA. On the left: atrophy of supraspinatus and infraspinatus muscles and rhomboid muscles (white arrow); on the right: scapular tilting and rotation caused by serratus anterior muscle weakness (white arrow with *) B. On the right: severe scapular winging caused by serratus anterior paralysis (white arrow) C. On the left: atrophy of supraspinatus and infraspinatus muscles (white arrow), and trapezius muscle (white arrow with *) showing underlying rhomboid muscles D. Severe atrophy of the deltoid muscle (white arrow) and moderate atrophy of the biceps brachii muscle (white arrow with *)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="hna-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
